The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients

Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium

(2011) Pamala A. Jacobson et al.   TRANSPLANTATION

Consequences of POR mutations and polymorphisms

(2010) Walter L. Miller et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19

(2010) Vishal Agrawal et al.   Pharmacogenetics and Genomics

Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase

(2010) Vishal Agrawal et al.   Pharmacogenetics and Genomics

Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients

(2010) Dirk R J Kuypers et al.   THERAPEUTIC DRUG MONITORING

The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test

(2009) Beatrice Oneda et al.   Pharmacogenetics and Genomics

Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions

(2008) K. Solez et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations

(2008) N. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacogenetics in solid organ transplantation: current status and future directions

(2007) Hylke de Jonge et al.   Transplantation Reviews